Krill Oil as Supplementation to Healthy Young Adults.

Study of the Effect of Krill Oil Supplement on Omega-3 Fatty Acid Index and Tolerance

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02053415

Enrollment

Registered

2014-02-03

Start date

2014-01-31

Completion date

2014-03-31

Last updated

2014-03-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Keywords

krill oil, omega-3 index, plasma lipid profile, tolerance, young adults

Brief summary

The purpose of this study is to examine whether 4 weeks daily intake of krill oil can change the omega-3 index (content of the long chained fatty acids EPA and DHA in relation to the total fatty acids) in the membrane in red blood cells. We investigate this at two different doses. Furthermore, the purpose of the study is also to examine the effect of the krill oil intake on plasma lipids (triacylglycerol, phospholipids and cholesterol), plasma fatty acid composition, as well as product tolerance in healthy, young individuals.

Interventions

DIETARY_SUPPLEMENTKrill oil low dose

3 capsules krill oil per day

DIETARY_SUPPLEMENTKrill oil high dose

9 capsules krill oil per day

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

SUPPORTIVE_CARE

Masking

SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 36 Years

Healthy volunteers

Yes

Inclusion criteria

* Healthy young adults

Exclusion criteria

* Disease/illness * Not able to swallow supplements in capsule form * Not willing to take blood samples

Design outcomes

Primary

Measure	Time frame	Description
Fatty acid composition in red blood cells (the membrane)	Day 0 (baseline), and day 28 (end)	Change in fatty acid composition and omega-3 index (sum of % EPA and DHA)

Secondary

Measure	Time frame	Description
Fasting plasma lipid status	Day o (baseline), and day 28 (end)	* Change in triacylglycerol levels. * Change in phospholipid levels. * Change in cholesterol levels (total, ester, free, HDL, LDL).
Fatty acid composition in plasma.	Day 0 (baseline), and day 28 (end)	Change in fatty acid composition and omega-3 index (sum of % EPA and DHA).
Fasting glucose and glucose tolerance.	Day 0 (baseline), and day 28 (end)	Change in fasting glucose and glucose tolerance.
Tolerance of and compliance with intervention	Day 28 (end)	Questionnaire-based

Countries

Norway

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026